Dare Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. on August 6, 2021, regarding events occurring on August 9, 2021. The company is a Delaware corporation focused on developing treatments for bacterial vaginosis.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a regulatory disclosure of a specific corporate event rather than a periodic financial report.
Material Changes and Events
- Regulatory Milestone: The U.S. Food and Drug Administration (FDA) accepted for filing Dare Bioscience's New Drug Application (NDA) for DARE-BV1, a treatment for bacterial vaginosis.
- Priority Review: The FDA granted priority review status to the NDA.
- Target Decision Date: The Prescription Drug User Fee Act (PDUFA) target date for the completion of the FDA's review is set for December 7, 2021.
Outlook, Risks, and Management Commentary
Management highlighted the acceptance of the NDA and the priority review designation as significant progress. The filing notes that the information is "furnished" and not "filed" for liability purposes under the Securities Exchange Act of 1934. No specific financial guidance or risk factors beyond the standard regulatory review process are detailed in this specific 8-K text.
Key Facts for Investor Verification
- Verify the PDUFA target date of December 7, 2021, for the DARE-BV1 NDA decision.
- Confirm the priority review status granted by the FDA for bacterial vaginosis treatment.
- Review the attached press release (Exhibit 99.1) for additional details on the clinical data supporting the NDA.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.